Immune Therapeutics, Inc. Announces Expansion of Board of Directors


ORLANDO, Fla., June 03, 2022 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTC: BB IMUN), a specialty pharmaceutical company involved in the development, commercialization, distribution and marketing of novel, patented therapies to combat chronic-threatening diseases through activation and modulation of the body’s immune system, announced today that it will expand its board of directors from two to five members.

Join the Board of Directors as of May 31st2022, will be Dr Stephen Wilson, Dr Clifford Selsky and Mr Robert Wilson who have been appointed for interim terms until an annual meeting of shareholders can be called to provide a formal vote on the nominees.

Dr. Stephen Wilson. Dr. Wilson is a qualified immunologist with over 25 years of experience in biomedical research and executive management. He is Chief Innovation Officer of Statera Biopharma, Inc. and Associate Clinical Professor at the University of California, San Diego. Previously, he served as Chief Operating Officer at the La Jolla Institute of Immunology; during his tenure, the Institute grew from $14 million in annual R&D to become a global leader in immunology research with nearly $1 billion in total operations as well as the world’s leading workplace by The Scientist magazine. His original research has been published in high-impact journals, and he has been principal investigator or co-principal investigator on over $75 million in grants and competitive awards, most recently developing the award-winning CoVID-19 rapid diagnostic test. X-Prize 2021. Dr. Wilson has served as an advisor to elite medical research organizations, served on national boards, and is a founding scientist and board member of Invivoscribe Technologies, Inc. , a leading company in the field of molecular diagnostics and oncology therapeutics. Dr. Wilson earned his doctorate from the University of Arizona College of Medicine in Immunology and was a member of the National Multiple Sclerosis Society and the National Institutes of Health.

Dr Selsky has been a practicing pediatrician in central Florida for twenty years. He is the founder of the Children’s Center for Cancer and Blood Disease at Florida Hospital Cancer Institute, which he established after training in pediatrics at Yale New Haven Hospital and a fellowship in hematology and of Pediatric Oncology at Yale University School of Medicine. Dr. Selsky is board certified in pediatrics, pediatric hematology and oncology, and palliative medicine. Currently, he is a pediatrician at Family First Pediatrics which he established in 2013.

Also, an accomplished scientist, Dr. Selsky earned his Ph.D. in Microbiology and Molecular Genetics at the University of Miami School of Medicine. He then did DNA repair research studies at the Harvard School of Public Health Radiobiology Laboratory and the Stanford University Biophysics Laboratory.

Mr Wilson has spent over 25 years building and launching businesses. As a business strategist, retail marketer and content developer, Robert is experienced in assessing business situations, conducting research, creating strategic plans, recommending solutions to management, monitoring competitors and measuring the results of marketing strategies. Robert has been involved in securing over $150 million in seed and angel funding, developing launch and pivot strategies, and identifying growth opportunities for over two dozen public companies ranging from the energy sector and electric vehicles to healthcare and lifestyle brands.

Note: Dr. Stephen Wilson and Mr. Robert Wilson are unrelated.

Kevin Phelps, CEO commented; “We are pleased to welcome our new members to the Board of Directors. The Company is at an inflection point in the development of its strategy and the experience and skills of these individuals will be invaluable moving forward. We are fortunate to be able to attract such talents.

Compensation terms for board members have not been finalized, but new board members have requested that their compensation be deferred until the company has met its strategic funding and operating goals.


Comments are closed.